Navigation Links
Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
Date:1/7/2008

s, in any subjects.

About EVT 302

EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B in development for smoking cessation. Its preclinical profile supports the potential for a superior safety profile over marketed MAO-B inhibitors and better tolerability compared to current treatments. In a Phase I single ascending dose study at Roche from whom the compound was in-licensed, EVT 302 was safe and well tolerated up to high dose levels and showed excellent pharmacokinetic properties with prolonged MAO-B inhibition offering the potential for once a week dosing at very low exposure levels. This could be a significant advantage for a condition where smokers' motivation for quitting can vary from day to day.

Two further Phase I studies with EVT 302 are currently ongoing: In March 2007, Evotec initiated a positron emission tomography (PET) study designed to assess the occupancy of MAO-B in the brain after the oral administration of EVT 302 in patients. This technique helps to determine the therapeutic dose range of EVT 302 for subsequent safety and efficacy studies. The study is expected to be completed in early 2008.

In November 2007, Evotec initiated a Phase I tyramine interaction study to confirm that there was no cardiovascular liability with foods that contain high amounts of tyramine. A first Phase II study to examine the effects of EVT 302 on craving following smoking cessation is planned to start in Q1 2008.

About Smoking Cessation

The market potential for smoking cessation therapies is enormous. There are 44.5 million smokers in the US alone, 70% of which report a desire to quit, and the average smoker will make six to nine attempts to quit during their lifetime. There is also strong health economic support for the benefits of quitting. The market is dominated by nicotine replacements such as patch and gum, and only two prescription therapies are currently approved. Any drug that could im
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
2. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
6. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
7. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... The Europe Thermal Protective Clothing market report ... revenue forecasts. It estimates the market to reach ... of 7.5%, from 2013 to 2018. , Browse ... Clothing market report for a glimpse of the ... tables and figures. , http://www.micromarketmonitor.com/market/europe-thermal-protective-clothing-5957050557.html , ...
(Date:11/27/2014)... USA (PRWEB) November 26, 2014 Biomedical ... accuracy, additive systems to enable 3D manufacture at the ... road conditions are among finalists in nine categories for ... The awards are sponsored by SPIE, the international ... Media . , Winners will be announced by industry ...
(Date:11/26/2014)... Chicago, IL (PRWEB) November 26, 2014 ... is giving customers a bevy of last-minute Thanksgiving ... coupon codes and offers across all product lines this ... Thanksgiving. , Thanksgiving, Black Friday, and Cyber Monday ... expressing its' own thanks to both loyal customers and ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 The ... City’s award-winning technology innovation centers, announced today that ... closing on December 1st. “Do you have a ... so, I want to know about it. AccelerateBaltimore ... idea to product in just 13 weeks.” ...
Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3
... Coalition,s Annual Meeting, FREMONT, Calif., Sept. 8 ... announced today that a,team of scientists at Stanford University ... at the Annual General Meeting of the,PAD Coalition. Led ... Eric T.,Fung, Chief Scientific Officer at Vermillion, Inc., the ...
... Sept. 8 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... enrolment in a Phase 2 clinical trial using ... in patients with advanced head and neck cancers. ... Cancer Therapy & Research Center,(CTRC) at The University ...
... International,Inc. (Nasdaq: CHDX ), a leading independent American provider ... China, today,announced that the Company will appear at the following ... held at the Grand Hyatt Hotel ... available for this event. -- ...
Cached Biology Technology:Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 2Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 3Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3Chindex International, Inc. Announces Appearances at Upcoming Investor Conferences 2Chindex International, Inc. Announces Appearances at Upcoming Investor Conferences 3
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
(Date:11/6/2014)... that predator runs so fast that it essentially blinds itself. ... fastest creature on Earth. Some of these half-inch-long beetles cover ... per hour). The fastest human can do about five body ... a person would have to hit 480 miles per hour. ... speeds, everything becomes a blur. They can,t gather enough light ...
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2Jet-fueled electricity at room temperature 2
... An international team led by scientists at The ... and Albert Einstein College of Medicine of Yeshiva University ... attacks the tuberculosis (TB) bacterium in two different ways. ... one of the major global health crises of our ...
... professors in Wayne State University,s Department of Physics kicked ... for Undergraduates (REU) program. This program aims to give ... and in particle and nuclear physics. According ... State,s College of Liberal of Arts, principal investigator and ...
... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ...
Cached Biology News:New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4Wayne State welcomes undergraduates from around the US for physics research experience 2'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
Black Polypropylene 384 Round Well Plate 70/Box...
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
... Synucleins are small, soluble proteins expressed ... tumors. The family includes three known proteins: ... The alpha and beta synuclein proteins are ... are seen mainly in presynaptic terminals. ...
Biology Products: